In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

被引:127
作者
Pfaller, MA
Boyken, L
Hollis, RJ
Messer, SA
Tendolkar, S
Diekema, DJ
机构
[1] Univ Iowa, Div Med Microbiol, Dept Pathol, Coll Med, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Epidemiol, Coll Med, Iowa City, IA 52242 USA
[3] Univ Iowa, Dept Med, Coll Med, Iowa City, IA 52242 USA
[4] Coll Publ Hlth, Iowa City, IA 52242 USA
关键词
D O I
10.1128/JCM.43.11.5425-5427.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Anidulafungin is an echinocandin antifungal agent with potent activity against Candida spp. We assessed the in vitro activity of anidulafungin against 2,235 clinical isolates of Candida spp. using the CLSI broth microdilution method. Anidulafungin was very active against Candida spp. (the MIC at which 90% of strains are inhibited [MIC90] was 2 mu g/ml when MIC endpoint criteria of partial inhibition [MIC-2] were used). Candida albicans, C. glabrata, C. tropicalis, C. krusei, and C. kefyr were the most susceptible species of Candida (MIC90, 0.06 to 0.12 mu g/ml), and C parapsilosis, C lusitaniae, and C guilliermondii were the least susceptible (MIC90, 0.5 to 2 mu g/ml). In addition, 315 fluconazole-resistant isolates were tested, and 99% were inhibited by <= 1 mu g/ml of anidulafungin. These results provide further evidence for the spectrum and potency of anidulafungin activity against a large and geographically diverse collection of clinically important isolates of Candida spp.
引用
收藏
页码:5425 / 5427
页数:3
相关论文
共 18 条
  • [11] Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States
    Ostrosky-Zeichner, L
    Rex, JH
    Pappas, PG
    Hamill, RJ
    Larsen, RA
    Horowitz, HW
    Powderly, WG
    Hyslop, N
    Kauffman, CA
    Cleary, J
    Mangino, JE
    Lee, J
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) : 3149 - 3154
  • [12] Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits
    Petraitiene, R
    Petraitis, V
    Groll, AH
    Candelario, M
    Sein, T
    Bell, R
    Lyman, CA
    McMillian, CL
    Bacher, J
    Walsh, TJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) : 2148 - 2155
  • [13] Caspofungin activity against clinical isolates of fluconazole-resistant Candida
    Pfaller, MA
    Messer, SA
    Boyken, L
    Rice, C
    Tendolkar, S
    Hollis, RJ
    Diekema, DJ
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (12) : 5729 - 5731
  • [14] Anidulafungin: an echinocandin antifungal
    Pfaller, MA
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (09) : 1183 - 1197
  • [15] Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates
    Pfaller, MA
    Messer, SA
    Boyken, L
    Rice, C
    Tendolkar, S
    Hollis, RJ
    Diekema, DJ
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (07) : 3117 - 3119
  • [16] In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents
    Pfaller, MA
    Messer, SA
    Coffman, S
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (04) : 763 - 766
  • [17] In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates
    Uzun, O
    Kocagoz, S
    Cetinkaya, Y
    Arikan, S
    Unal, S
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) : 1156 - 1157
  • [18] Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents
    Zhanel, GG
    Karlowsky, JA
    Zelenitsky, SA
    Turik, MA
    Hoban, DJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) : 2446 - 2448